Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates

Epidemiology

Volumn 11, Issue 2, 2000, Pages 167-170

  Tarone, Robert E ^a   Chu, Kenneth C ^a   Brawley, Otis W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Mortality; Prostate neoplasms; Race; Survival; Time trends; Tumor staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL; PROSTATE CANCER;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; UNITED STATES;

EID: 0034003053     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-200003000-00014     Document Type: Article

References (16)

1. Gann PH. Interpreting recent trends in prostate cancer incidence and mortality (Editorial Comment). Epidemiology 1997;8:117-120.
2. Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DW, Dibble RL. The fall in incidence of prostate carcinoma. Cancer 1996;77:1342-1348.
3. Schwartz KL, Severson RK, Gurney JG, Montie JE. Trends in the stage specific incidence of prostate carcinoma in the Detroit Metropolitan area. Cancer 1996;78:1260-1266.
4. Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology 1997;8:126-131.
5. Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol 1997;158:1427-1430.
6. Brawley OW. Prostate carcinoma incidence and patient mortality. Cancer 1997;80:1857-1863.
7. Smart CR. The results of prostate cancer screening in the U.S. as reflected in the Surveillance, Epidemiology, and End Results Program. Cancer 1997; 80:1835-1844.
8. Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States? Cancer 1998;82:249-251.
9. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998;52:444-449.
10. Barry MJ. PSA screening for prostate cancer: the current controversy: a viewpoint. Ann Oncol 1998;9:1297-1300.
11. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legier JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS. Interpreting trends in prostate cancer. I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017-1024.
12. Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control 1998;9: 519-527.
13. Tarone RE, Chu KC, Gaudette LA. Birth cohort and calendar period trends in breast cancer mortality in the United States and Canada. J Natl Cancer Inst 1997;89:251-256.
14. Surveillance, Epidemiology and End Results (SEER) Cancer Incidence Public-Use Database, 1973-1996, August 1998 Submission. CD-Rom. Bethesda, MD: National Cancer Institute, 1999.
15. Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, Chute CG, Lieber MM. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. J Am Med Assoc 1995;274:1445-1449.
16. Martin JA, Smith BL, Mathews TJ, Ventura SJ. Births and deaths: preliminary data for 1998. Natl Vital Stat Rep 1999;47:29.